SUBSEQUENT EVENT (Details) - Subsequent Events - XenoTherapeutics Inc. |
Jul. 01, 2025
USD ($)
$ / shares
|
|---|---|
| SUBSEQUENT EVENT | |
| Number of contingent value rights | 1 |
| Contingent value rights payment, period | 18 months |
| Share price | $ / shares | $ 1.91 |
| Termination fee payable | $ 2,500,000 |
| Maximum | |
| SUBSEQUENT EVENT | |
| Contingent consideration, liability | $ 2,950,000 |
| Contingent consideration value per share | $ / shares | $ 0.06 |
| X | ||||||||||
- Definition The number of contingent value rights ("CVR") to be received as consideration in business combination. No definition available.
|
| X | ||||||||||
- Definition The value per share attributed to contingent consideration issued in business combination. No definition available.
|
| X | ||||||||||
- Definition Threshold period of payment of contingent value rights, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Amount of termination fee payable as part of business combination. No definition available.
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. No definition available.
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|